Unlocking Immune Potential with
Innovative Metabolic Reprogramming

Pilatus Biosciences pioneers innovative therapies using first-in-class antibodies and bifunctional proteins to target metabolic checkpoints, reprogramming the immune microenvironment to address cancer and immune-related diseases.

LEARN more

Ongoing Phase 1 Clinical Trials with our Lead Candidate PLT012

First-in-class, anti-CD36 monoclonal antibody; metabolic checkpoint inhibitor targeting lipid-mediated immunosuppression

More Information

PLT012: FDA Designations

Fast Track Designation

Granted by the FDA to facilitate development and expedite review of PLT012 for hepatocellular carcinoma, a serious condition with high unmet medical need.

Orphan Drug Designation

Granted by the FDA to support the development of PLT012 for hepatocellular carcinoma and intrahepatic bile duct cancer, including regulatory incentives and potential market exclusivity.

“At Pilatus Biosciences, innovation and integrity drive our mission to transform disease treatment. Through excellence and collaboration, we shape a future of groundbreaking breakthroughs together.”

Raven Lin | Co-Founder and Chief Executive Officer of Pilatus Biosciences

Mechanism of Action:
Targeting Maladaptive Metabolism

Mission

Our mission is to create innovative immunotherapies that unlock the immune system's potential and improve lives by turning once-untreatable diseases into manageable conditions.

Partners

Partner with Us to Advance Immune Innovation

We are currently seeking strategic partners and investors to accelerate the development and commercialization of our lead candidate, PLT012, and expand our pioneering pipeline.

If you are exploring high-potential investment opportunities in biotech front or looking to collaborate on cutting-edge medical science, Pilatus invites you to connect with us!